From GlobeNewswire: 2024-08-06 16:40:00

BioVie Inc. completed a reverse stock split of its Class A common stock at an exchange ratio of 1-for-10, effective now. The Company’s stock will continue trading on Nasdaq under the symbol “BIVI” with a new CUSIP number. The reverse split was approved by stockholders at a Special Meeting on July 29, 2024. BioVie Inc. is a clinical-stage company developing drug therapies for neurological disorders and liver disease. Their drug candidate bezisterim targets neuroinflammation in diseases like Alzheimer’s and Parkinson’s. Another drug candidate, BIV201, is being evaluated for treating ascites due to chronic liver cirrhosis.



Read more at GlobeNewswire: BioVie Inc. Announces Reverse Stock Split